

Mathilde Cm Kouwenhoven

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/120841/publications.pdf>

Version: 2024-02-01

57
papers

6,099
citations

168829

31
h-index

182931

54
g-index

60
all docs

60
docs citations

60
times ranked

8218
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of Antiseizure Medication Duotherapies in Patients With Glioma. <i>Neurology</i> , 2022, 99, .	1.5	15
2	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 2539-2545.	0.8	23
3	First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid. <i>Epilepsia</i> , 2021, 62, 1119-1129.	2.6	36
4	The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide. <i>Journal of Neuro-Oncology</i> , 2021, 154, 73-81.	1.4	9
5	A multidisciplinary neuro-oncological triage panel reduces the time to referral and treatment for patients with a brain tumor. <i>Neuro-Oncology Practice</i> , 2021, 8, 559-568.	1.0	1
6	Non-invasively measured brain activity and radiological progression in diffuse glioma. <i>Scientific Reports</i> , 2021, 11, 18990.	1.6	13
7	NCOG-15. THE EFFECTIVENESS OF ANTIEPILEPTIC DRUG DUOTHERAPIES IN GLIOMA PATIENTS: A MULTICENTER OBSERVATIONAL COHORT STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi155-vi155.	0.6	0
8	QOLP-05. HEALTH-RELATED QUALITY OF LIFE IN LOW-GRADE GLIOMA SURVIVORS 26 YEARS AFTER DIAGNOSIS. <i>Neuro-Oncology</i> , 2021, 23, vi183-vi183.	0.6	0
9	To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. <i>Anticancer Research</i> , 2019, 39, 3303-3309.	0.5	19
10	The Ticking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation. <i>Drug Resistance Updates</i> , 2019, 43, 29-37.	6.5	33
11	Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study. <i>Journal of Neuro-Oncology</i> , 2019, 142, 463-470.	1.4	26
12	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	13.7	320
13	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018, 20, 873-884.	0.6	119
14	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. <i>BMJ Open</i> , 2017, 7, e014961.	0.8	69
15	Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. <i>Journal of Clinical Oncology</i> , 2013, 31, 344-350.	0.8	1,003
16	New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. <i>European Journal of Cancer</i> , 2013, 49, 3477-3485.	1.3	51
17	Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. <i>Acta Neuropathologica</i> , 2012, 123, 841-852.	3.9	77
18	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours – a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Histopathology</i> , 2012, 60, 885-894.	1.6	44

#	ARTICLE	IF	CITATIONS
19	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. Journal of Clinical Oncology, 2012, 30, 2-2.	0.8	19
20	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. Journal of Clinical Oncology, 2012, 30, 2-2.	0.8	6
21	MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. Journal of Neuro-Oncology, 2011, 101, 405-417.	1.4	25
22	Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-Oncology, 2011, 103, 221-230.	1.4	21
23	First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro-Oncology, 2011, 13, 235-241.	0.6	60
24	Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinibâ€”A Phase II Trial. Molecular Cancer Therapeutics, 2011, 10, 1102-1112.	1.9	170
25	Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro-Oncology, 2009, 11, 737-746.	0.6	71
26	Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology. Cancer Research, 2009, 69, 9065-9072.	0.4	575
27	Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034. Journal of Clinical Oncology, 2009, 27, 1268-1274.	0.8	503
28	Chromosome 1p loss evaluation in anaplastic oligodendroglomas. Neuropathology, 2008, 28, 440-443.	0.7	29
29	Stem Cellâ€”Related â€œSelf-Renewalâ€”Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma. Journal of Clinical Oncology, 2008, 26, 3015-3024.	0.8	631
30	Intratumoral Distribution of 1p Loss in Oligodendroglial Tumors. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1118-1123.	0.9	9
31	Panel Review of Anaplastic Oligodendrogloma From European Organization for Research and Treatment of Cancer Trial 26951. Journal of Neuropathology and Experimental Neurology, 2007, 66, 545-551.	0.9	143
32	Panel review of a set of anaplastic oligodendrogloma of EORTC trial 26951: interobserver variation, correlation with 1p/19q loss and clinical outcome. FASEB Journal, 2007, 21, A26.	0.2	0
33	Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendroglomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. Journal of Clinical Oncology, 2006, 24, 2715-2722.	0.8	690
34	1p/19q loss within oligodendrogloma is predictive for response to first line temozolomide but not to salvage treatment. European Journal of Cancer, 2006, 42, 2499-2503.	1.3	111
35	Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-BarrÃ© syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neuroimmunology, 2005, 159, 165-176.	1.1	36
36	Gene Expression Profiles Associated with Treatment Response in Oligodendroglomas. Cancer Research, 2005, 65, 11335-11344.	0.4	102

#	ARTICLE	IF	CITATIONS
37	Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables. <i>European Journal of Neurology</i> , 2003, 10, 529-535.	1.7	28
38	Cytokines in multiple sclerosis: methodological aspects and pathogenic implications. <i>Multiple Sclerosis Journal</i> , 2002, 8, 396-404.	1.4	47
39	Non-T _H 1 cytokines are augmented systematically early in Guillain-Barré syndrome. <i>Neurology</i> , 2002, 58, 476-478.	1.5	35
40	Recruitment of dendritic cells to the cerebrospinal fluid in bacterial neuroinfections. <i>Journal of Neuroimmunology</i> , 2002, 122, 106-116.	1.1	102
41	Monocyte-derived dendritic cells express and secrete matrix-degrading metalloproteinases and their inhibitors and are imbalanced in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 126, 161-171.	1.1	51
42	Elevated expression of CCR5 by myeloid (CD11c +) blood dendritic cells in multiple sclerosis and acute optic neuritis. <i>Clinical and Experimental Immunology</i> , 2002, 127, 519-526.	1.1	51
43	Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes. <i>Journal of Autoimmunity</i> , 2001, 16, 463-470.	3.0	66
44	Systemic Immune Response in Whiplash Injury and Ankle Sprain: Elevated IL-6 and IL-10. <i>Clinical Immunology</i> , 2001, 101, 106-112.	1.4	19
45	Dendritic cells derived from patients with multiple sclerosis show high CD1a and low CD86 expression. <i>Multiple Sclerosis Journal</i> , 2001, 7, 95-99.	1.4	38
46	Chemokines and their receptors in whiplash injury: elevated RANTES and CCR-5. <i>Journal of Clinical Immunology</i> , 2001, 21, 272-277.	2.0	16
47	Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. <i>Journal of Clinical Immunology</i> , 2001, 21, 365-375.	2.0	33
48	Monocytes in multiple sclerosis: phenotype and cytokine profile. <i>Journal of Neuroimmunology</i> , 2001, 112, 197-205.	1.1	97
49	IL-12/IL-12R system in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2001, 114, 242-252.	1.1	25
50	Enzyme-Linked Immunospot Assays Provide a Sensitive Tool for Detection of Cytokine Secretion by Monocytes. <i>Vaccine Journal</i> , 2001, 8, 1248-1257.	2.6	23
51	Dendritic cells derived from patients with multiple sclerosis show high CD1a and low CD86 expression. <i>Multiple Sclerosis Journal</i> , 2001, 7, 95-99.	1.4	5
52	Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF- α)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN- β) treatment. <i>Clinical and Experimental Immunology</i> , 2000, 120, 147-153.	1.1	96
53	Multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2000, 108, 236-243.	1.1	83
54	IL-12 ELISPOT ASSAYS TO DETECT AND ENUMERATE IL-12 SECRETING CELLS. <i>Cytokine</i> , 2000, 12, 1218-1224.	1.4	11

#	ARTICLE	IF	CITATIONS
55	Multiple Sclerosis: Levels of Interleukin-10-Secreting Blood Mononuclear Cells are Low in Untreated Patients but Augmented During Interferon-beta-1b Treatment. <i>Scandinavian Journal of Immunology</i> , 1999, 49, 554-561.	1.3	67
56	Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. <i>Journal of Neuroimmunology</i> , 1999, 99, 82-90.	1.1	91
57	Metalloproteinases and their Tissue Inhibitors in Multiple Sclerosis. <i>Journal of Autoimmunity</i> , 1999, 12, 297-303.	3.0	56